Nuvo Pharmaceuticals Inc banner

Nuvo Pharmaceuticals Inc
TSX:MRV

Watchlist Manager
Nuvo Pharmaceuticals Inc Logo
Nuvo Pharmaceuticals Inc
TSX:MRV
Watchlist
Price: 1.35 CAD Market Closed
Market Cap: CA$15.4m

Nuvo Pharmaceuticals Inc
Gross Profit

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Nuvo Pharmaceuticals Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Nuvo Pharmaceuticals Inc
TSX:MRV
Gross Profit
CA$45.1m
CAGR 3-Years
12%
CAGR 5-Years
34%
CAGR 10-Years
9%
Bausch Health Companies Inc
TSX:BHC
Gross Profit
$7.5B
CAGR 3-Years
9%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Canopy Growth Corp
TSX:WEED
Gross Profit
CA$73.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Gross Profit
$62.8m
CAGR 3-Years
60%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Gross Profit
CA$207.7m
CAGR 3-Years
15%
CAGR 5-Years
21%
CAGR 10-Years
79%
No Stocks Found

Nuvo Pharmaceuticals Inc
Glance View

Market Cap
15.4m CAD
Industry
Pharmaceuticals

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. The company is headquartered in Mississauga, Ontario and currently employs 100 full-time employees. The firm is engaged in offering diversified portfolio of commercial products. The company operates through three segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment is comprised of products commercialized by the Company in Canada. The company includes products, such as Blexten, Cambia, Suvexx and NeoVisc, as well as mature products. The Production and Service Business segment includes sale of products manufactured by the Company from its manufacturing facility in Varennes, Quebec or contracted by Miravo Ireland from its international headquarters in Dublin, Ireland, as well as service for testing, development and related quality assurance and quality control services provided by the Company. The Licensing and Royalty Business segment includes the revenue by the licensing of intellectual property and ongoing royalties from licensing agreements with partners.

MRV Intrinsic Value
Not Available

See Also

What is Nuvo Pharmaceuticals Inc's Gross Profit?
Gross Profit
45.1m CAD

Based on the financial report for Sep 30, 2022, Nuvo Pharmaceuticals Inc's Gross Profit amounts to 45.1m CAD.

What is Nuvo Pharmaceuticals Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
9%

Over the last year, the Gross Profit growth was -3%. The average annual Gross Profit growth rates for Nuvo Pharmaceuticals Inc have been 12% over the past three years , 34% over the past five years , and 9% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett